| Species |
Human |
| Protein Construction |
LAIR1/CD305 (Gln22-His163)_x000D_
Accession # Q6GTX8-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized LAIR1/CD305, His & Avi, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiLAIR1 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
18.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-36 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
LAIR1 (leukocyte-associated Ig-like receptor-1, designated CD305) is an approximately 40 kDa type I transmembrane inhibitory glycoprotein belonging to the Ig superfamily.LAIR1 functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation. |
| Synonyms |
CD305; HLAIR1; LAIR1; LAIR-1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
